You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 13, 2024

CLINICAL TRIALS PROFILE FOR ALINIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Alinia

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00130390 ↗ Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease Terminated Romark Laboratories L.C. Phase 2 2005-08-01 The primary objective of this study is to evaluate the efficacy and safety of nitazoxanide compared to a placebo in reducing the signs and symptoms of mild to moderate active Crohn's disease in adults.
NCT00304356 ↗ Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection Completed Baylor College of Medicine Phase 3 2004-01-01 The purpose of this study is for compassionate use of nitazoxanide in the treatment of diarrheal disease due to Clostridium difficile infection when the patient has failed previous treatment with metronidazole or vancomycin.
NCT00304356 ↗ Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection Completed Daniel M. Musher MD Phase 3 2004-01-01 The purpose of this study is for compassionate use of nitazoxanide in the treatment of diarrheal disease due to Clostridium difficile infection when the patient has failed previous treatment with metronidazole or vancomycin.
NCT00304356 ↗ Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection Completed VA Medical Center, Houston Phase 3 2004-01-01 The purpose of this study is for compassionate use of nitazoxanide in the treatment of diarrheal disease due to Clostridium difficile infection when the patient has failed previous treatment with metronidazole or vancomycin.
NCT00384527 ↗ Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease Terminated Romark Laboratories L.C. Phase 3 2006-12-01 The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).
NCT00421434 ↗ Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C Completed Romark Laboratories L.C. Phase 2/Phase 3 2006-06-01 The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon and nitazoxanide-peginterferon-ribavirin combination regimens compared to the standard of care (peginterferon-ribavirin) in treating chronic hepatitis C genotype 4. The study will also evaluate the effect of the studied treatment regimens on end of treatment virologic response, ALT normalization and safety parameters.
NCT00495391 ↗ Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C Completed Romark Laboratories L.C. Phase 2 2007-07-01 The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to treatment with peginterferon and ribavirin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Alinia

Condition Name

Condition Name for Alinia
Intervention Trials
Chronic Hepatitis C 4
HIV Infection 2
Malnutrition 1
Crohn's Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Alinia
Intervention Trials
Hepatitis A 6
Hepatitis 6
Hepatitis C 6
Hepatitis, Chronic 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Alinia

Trials by Country

Trials by Country for Alinia
Location Trials
United States 85
Australia 7
Egypt 4
New Zealand 3
Canada 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Alinia
Location Trials
New York 7
California 6
Georgia 5
Florida 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Alinia

Clinical Trial Phase

Clinical Trial Phase for Alinia
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2/Phase 3 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Alinia
Clinical Trial Phase Trials
Completed 13
Terminated 2
Unknown status 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Alinia

Sponsor Name

Sponsor Name for Alinia
Sponsor Trials
Romark Laboratories L.C. 9
Telethon Kids Institute 2
The University of Western Australia 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Alinia
Sponsor Trials
Other 13
Industry 10
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.